Elekta stock steadies after dividend and analyst update

Published on 09/07/2026 at 13:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock steadied after a dividend update and a fresh analyst note. The Swedish medtech group also shows 2026 year-to-date weakness and a 14.14 percent gap to the average target.

Moderner Bestrahlungsraum mit High-Tech-Linearbeschleuniger in blauem Klinik-Ambiente — Fotorealistischer Bestrahlungsraum zeigt Elekta AB SE0000163628 mit modernem Linearbeschleuniger in klinischer High-Tech-Umgebung, Illustration mit AI erstellt.

Elekta AB (publ) stock (SE0000163628) traded at 51.65 SEK at 10:59:10 on September 7, 2026, after a 1.24 percent daily drop and a 5-day loss of 5.25 percent. Zonebourse The same snapshot shows the stock down 9.34 percent year to date, while the average analyst target stands at 59.69 SEK.

Dividend and target update

Zonebourse also reported on September 7, 2026 that Elekta's board approved a dividend payable in two installments on September 10, 2026 and March 10, 2027. The same update lists a consensus recommendation of hold, 14 analysts, a last close of 52.30 SEK and a target gap of 14.14 percent.

For investors, the mix is clear: the stock is lower on the year, but the dividend schedule and the 59.69 SEK consensus target keep valuation in view. The pricing gap versus last close is 7.69 SEK.

Commanders and margins

Zonebourse describes Elekta as a medtech company with 3,996 employees and advanced medical technology for cancer and brain disorder care. The same page frames the latest note around improving profitability and a recovering order book.

The current market value shown on the same quote page is 2.17 billion USD, and the OTC listing snapshot puts EKTA.F at 5.650 USD on September 3, 2026 with 1,000 shares traded. That moves the stock 8.06 percent lower for 2026 on the OTC line, a clearer yardstick than broad wording.

Revenue base

MarketScreener shows Elekta's revenue at 16.718 billion SEK and 1.747 billion USD, with 3,996 employees and a revenue per employee of 4,183,684 SEK. The same snapshot gives the Stockholm line at 52.30 SEK and the OTC line at 5.650 USD on September 3, 2026.

The 20-day moving average is 4.242, the 50-day moving average is 4.431 and the 100-day moving average is 5.617 on the same market page. That puts the current Stockholm quote below the short- and medium-term averages, but only 0.58 percent under the 100-day line.

Elekta's main product

Elekta's core business remains radiotherapy and radiosurgery systems for cancer care, together with software that supports clinical workflows. The latest company profile on the market page points to that installed-base model as the operating anchor behind the recovery narrative.

Stock and venue

Elekta stock closed the latest Stockholm snapshot at 52.30 SEK, while the OTC line printed 5.650 USD on September 3, 2026. The relevant venue for the home listing is Nasdaq Stockholm.